CAJ | 학술논문

研究发现阿尔茨海默病(AD)的许多病理特征和认知功能下降可能与脑内胰岛素抵抗有关。对AD动物模型和轻度认知功能障碍患者的脑组织进行研究，结果表明应用胰高血糖素样肽1(GLP-1)类似物如利拉鲁肽、艾塞那肽治疗后，脑内胰岛素抵抗和许多病理特征减少或是逆转。这一研究结果为GLP-1类似物对AD的潜在治疗研究提供理论基础。对GLP-1及其类似物在AD中的潜在治疗作用做一综述。
연구발현아이자해묵병(AD)적허다병리특정화인지공능하강가능여뇌내이도소저항유관。대AD동물모형화경도인지공능장애환자적뇌조직진행연구，결과표명응용이고혈당소양태1(GLP-1)유사물여리랍로태、애새나태치료후，뇌내이도소저항화허다병리특정감소혹시역전。저일연구결과위GLP-1유사물대AD적잠재치료연구제공이론기출。대GLP-1급기유사물재AD중적잠재치료작용주일종술。
Alzheimer’s disease (AD) was found many pathological features and cognitive decline that may be associated with insulin resistance in the brain. The study of AD animal models and patients with mild cognitive dysfunction (MCI) of brain tissue showed that insulin resistance and many pathological features may be reduced or reversed after the treatment with glucagon-likepeptide 1 analogue such as liraglutide, exenatide lyxumia. This is a theoretical basis for the potential treatment of GLP-1 analogues on the results of this study for AD. GLP-1 and its analogues’ potential therapeutic role in AD were reviewed.